Core Viewpoint - Longkun Technology (301305.SZ) has received approval from the National Health Commission for its self-developed human milk oligosaccharides (HMOs) product 2'-FL (2'-fucosyllactose), marking a significant milestone in the domestic HMO industry [1] Group 1 - The approval of 2'-FL follows the earlier approval of LNnT (lactose-N-tetraose), making it the second core HMO component approved in China [1] - This achievement represents an important advancement in the company's innovative research and compliance layout for the entire HMO value chain [1] - The approval is a key milestone for promoting the independent and large-scale development of the domestic HMO industry [1]

为更好地推动科技金融与科技产业化的发展，对母基金在中国资本市场里所发挥的重要作用进 行系统研究，发挥政府出资产业投资基金等的资源和战略优势，加强政府对社会资本的管理和 引导，促进社会资本流向创新创业型企业和实体经济，推动中国投资行业特别是母基金行业的 健康发展， "中国国际科技促进会母基金分会"（简称"科促会母基金分会"）成立。科促会母基 金分会领导班子所在机构及参会机构 共 8 7 家，科促会母基金分会于每周二更新相关机构的一 周资讯。 01 这支长三角母基金招GP了 为规范、高效地遴选长三角生态绿色一体化发展示范区投资基金（以下简称 "示范区投资基 金"或"母基金"）的子基金管理机构，根据《长三角生态绿色一体化发展示范区投资基金管理 办法》（以下简称《办法》）等相关规定，遵循公开、公平、公正的原则，现面向社会公开遴 选子基金管理机构。 有关事项公告如下：一、遴选基本原则 （一）公开公平公正原则。遴选过程面向社会公开发布、程序规范透明、条件标准统一，保障 各类申报机构平等参与，确保客观公正。（二）依法依规审慎原则。严格遵循法律法规、行业 监管规定以及《办法》等制度要求，规范履行评审、决策程序，加强风险识别与 ...

关键词| 未来食品&农业 | 虹摹生物 【SynBioCon】 获 悉， 2月4日， 虹摹生物科技（上海）有限公司 与 合肥高新区 签署落地协议，标志着 总投资约5.1亿元的合成生物科技项目 正 式落户合肥高新区。 合肥 市委常委、副市长袁飞，蒙牛集团副总裁陈易一、郭晓斌见证签约。 该项目总用地50亩，分两期建设，项目建成后，将成为国内领先的母乳低聚糖（HMOs）产业化生产基地。二期全面达产后，年产能将达3000吨，预 计年产值15亿元。 虹摹生物是蒙牛集团体系孵化的合成生物领域创新型企业，专注于HMOs的自主研发与产业化，致力于打破国际品牌在该领域的长期垄断，推动国产婴 儿配方奶粉向高端化升级。公司是中国首家及唯一同时通过2'-岩藻糖基乳糖(2'-FL)、乳糖-N-新四糖(LNnT)和3'-唾液酸乳糖钠盐(3'-SL)三款HMOs 产品卫健委审批的企业，并已通过国内头部乳制品企业的供应商审核。 近年来，高新区积极布局合成生物产业新赛道，现已集聚凯赛生物等相关企业约30家，构建起覆盖基础研究、中试放大到产业化的全链条创新体系。通 过出台专项政策、引导产业基金协同等举措，持续优化产业生态，加速培育发展新动能。下 ...

Core Insights - The biomanufacturing sector is poised for significant growth by 2025, driven by strategic investments from state-owned enterprises and leading public companies, establishing a solid foundation for industry capital [1][2] - Funding trends indicate a shift from early-stage R&D to capacity expansion and commercialization, with a notable increase in financing activities across the sector [2] Financing Events - In January 2025, Liying Biotechnology secured nearly 100 million yuan in Series A funding led by Tianshui Bay Technology [3] - In February 2025, Ruide Lin Biotechnology completed over 500 million yuan in Series C funding, marking the largest single financing event in the biomanufacturing sector for the year [6] - In March 2025, Zhongke Guosheng raised 200 million yuan in A+ round funding, with participation from CITIC Jinshi and PwC Capital [7][8] - In August 2025, Yixi Biotechnology completed nearly 200 million yuan in Series A funding, focusing on the production of human milk oligosaccharides [9][11] - In December 2025, Tangzhi Pharmaceutical raised over 100 million yuan, with investments from AstraZeneca and other funds, focusing on nucleotides and sugar science products [16] Industry Trends - The biomanufacturing industry is experiencing a collective confidence boost, as evidenced by 17 companies achieving financing close to or exceeding 100 million yuan in 2025 [2] - The overseas market is also thriving, with leading companies securing over $320 million in funding within a year, particularly in the fermented protein food sector [4] - Companies like Colossal Bioscience are pushing the boundaries of biotechnology, having raised significant funds to pursue ambitious projects such as reviving extinct species [17]

Core Insights - The article highlights the growth trajectory of Jiabiou, a pioneer in China's food biotechnology sector, emphasizing its strategic alignment with national policies and global technological trends [2][4][42] - Jiabiou has transitioned from a focus on nutritional ingredient development to becoming a key player in supporting the national biomanufacturing strategy, showcasing its commitment to innovation and industry leadership [6][10][42] Financial Performance - Jiabiou's revenue has steadily increased from 312 million yuan in 2019 to an expected 555 million yuan in 2024, reflecting a compound annual growth rate of 12.2% [2][13] - In the first three quarters of 2025, the company achieved revenue of 428 million yuan and a net profit of 129 million yuan, marking a significant year-on-year growth of 54.16% [2][14] Innovation and R&D - The company has invested heavily in R&D, with expenditures reaching 47.9 million yuan in 2024, accounting for 8.6% of its revenue, and a total of 119 million yuan over the past three years [16][17] - Jiabiou has developed a comprehensive technology platform that integrates various biological manufacturing techniques, significantly enhancing production efficiency and product quality [17][27] Global Expansion and Market Position - Jiabiou has established three international-standard production bases and has received key certifications, enabling it to penetrate major global markets [18][19] - The company has formed strategic partnerships with leading distributors, enhancing its market reach and establishing a robust sales network [18][19] Social Responsibility and Industry Impact - Jiabiou actively participates in setting industry standards and promoting sustainable practices, aligning its operations with national carbon reduction goals [20][19] - The company has been recognized for its contributions to the biomanufacturing sector, including being listed among the first batch of "biomanufacturing landmark products" by the Ministry of Industry and Information Technology [5][26] Strategic Positioning - Jiabiou has built a competitive advantage through a combination of policy alignment, technological barriers, and comprehensive supply chain capabilities, positioning itself favorably for future growth [7][9][42] - The company is poised to leverage the opportunities presented by the "14th Five-Year Plan" and the emerging biomanufacturing sector, aiming to become a leader in high-quality development [10][29]

Core Viewpoint - The health raw materials sector is evolving towards more precise, efficient, and personalized solutions, driven by technological advancements and regulatory improvements [3][7]. Group 1: Key Trends - The development and application of health raw materials are shifting from generalized "nutritional supplements" to refined solutions targeting specific demographics and health scenarios [3]. - Key trends include the upgrade to precision and scenario-based applications, focusing on specific health needs such as menopause care and metabolic management [3]. - The use of patented technologies, such as precision fermentation and advanced extraction processes, is enhancing the bioavailability and efficacy of raw materials, addressing previous cost and utilization challenges [3]. Group 2: Highlighted Raw Materials - Marine-derived active ingredients, such as phospholipid Omega-3 from krill oil, are noted for their significant effects on heart health, supported by pure Antarctic sources and patented technologies [3]. - Ergothioneine, while not yet approved as a new food ingredient in China, is widely used in the US, Europe, and Japan, showing promise in cosmetics and dietary supplements due to technological breakthroughs that alleviate scarcity and cost issues [3]. - Human milk oligosaccharides (HMOs) are gaining attention for their applications in infant formula and regular foods, with regulatory environments improving globally, including FDA approvals in the US and specific approvals in China [3][8]. - Reduced coenzyme Q10, enhanced through precision fermentation, is pushing nutritional supplements towards greater efficiency and precision [3]. Group 3: Market Dynamics - The market for health raw materials is increasingly focused on quality and transparency, with consumers prioritizing active ingredient content, standardization, and traceability [8]. - The cultivation of products using wild-simulated methods is gaining popularity due to balanced composition and high activity, making compliance and process transparency key competitive factors [8]. - Exosomes are emerging in regenerative medicine and precision healthcare, showing potential in areas like neurological disease repair and non-invasive tumor diagnostics, although most applications are still in early research stages [8].

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" [5] Core Insights - The application of Human Milk Oligosaccharides (HMOs) is expected to accelerate, driven by their recognized nutritional benefits and expanding regulatory approvals [3] - The infant formula market is experiencing increased concentration, with the top 10 companies' market share rising from 68% in 2017 to 83% in Q3 2025, indicating a shift towards premium product offerings that include HMOs [2] - The potential market space for HMOs in the Chinese infant formula sector is estimated to be between 5.86 billion to 11.72 billion yuan, based on projected production and pricing [2] Summary by Sections HMO Nutritional Benefits - HMOs are the third largest nutritional component in breast milk, consisting of various structures that contribute positively to infant health, including growth, gut health, immunity, and cognitive development [1] Market Dynamics - The implementation of stringent new standards for infant formula has led to significant market consolidation and a focus on nutritional enhancement, with major brands introducing HMO-enriched products [2] - The expected production of infant formula in China for 2024 is approximately 1.563 million tons, with a significant portion anticipated to be high-end products requiring HMO addition [2] Regulatory Developments - Recent approvals by health authorities to expand the use of HMOs in various food products indicate a growing recognition of their value, which could lead to exponential market growth if HMOs are utilized beyond infant formula [3] - Companies like Ganbaiyou and Qiu Tian Man Man are already responding to these regulatory changes by launching HMO-added products [3] Company Focus - Companies such as Langkun Technology, Baolingbao, and Jiabiyou are actively developing HMO production capabilities, with significant annual production capacities planned [10]

Investment Rating - The investment rating for the company is "Buy" [1] Core Insights - The company's revenue, net profit attributable to shareholders, and net profit after deducting non-recurring gains and losses for Q3 2025 were CNY 727 million, CNY 41 million, and CNY 34 million, respectively, representing year-on-year growth of 12.23%, 30.21%, and 11.72% [2] - The significant growth in performance is attributed to the substantial increase in sales of core products such as sugar-reduced sweeteners, prebiotics, and dietary fibers, along with improved gross margins due to cost reduction and efficiency enhancement [2][3] - The company's three core products accounted for 61.5% of revenue, with a gross margin contribution of 68.6%, and their sales revenue grew by 25.8% year-on-year [3] - The approval of HMO (Human Milk Oligosaccharides) for infant formula has been finalized, allowing for the expansion of product offerings in this category [4] - The gross margin for Q3 2025 was 13.54%, an increase of 1.76 percentage points year-on-year, while the gross margin for core products improved by 5.3 percentage points [5] Summary by Sections Financial Performance - For the first three quarters of 2025, the company reported revenue of CNY 2.126 billion, net profit attributable to shareholders of CNY 134 million, and operating cash flow of CNY 158 million, reflecting year-on-year growth of 15.98%, 32.58%, and 62.38% respectively [2] - The company’s inventory decreased by 8.06% year-on-year, with inventory turnover days reduced to 39 days [6] Investment Recommendations - The company is positioned as a leader in the functional sugar industry, with a strong market share in sugar-reduced sweeteners, prebiotics, and dietary fibers [7] - Short-term outlook suggests further improvement in gross margins due to declining corn prices and production efficiency [7] - Mid-term prospects include accelerated approval for allulose, which is expected to open up the domestic market [7] - Long-term growth is anticipated from the launch of high-value products such as HMOs, DHA, and sugar-free resistant dextrin [7] Financial Projections - Revenue projections for 2025, 2026, and 2027 are CNY 2.718 billion, CNY 2.966 billion, and CNY 3.211 billion, respectively, with corresponding net profits of CNY 179 million, CNY 222 million, and CNY 269 million [9][11]

Financial Performance - In the first half of 2025, the company achieved total revenue of 139,923.89 million yuan, a year-on-year increase of 18.02% [3] - The net profit attributable to shareholders, after deducting share-based payment expenses, was 9,532.72 million yuan, with a year-on-year growth of 32.15% [3] - The second quarter of 2025 saw revenue of 71,444.25 million yuan, a year-on-year increase of 12.63% and a quarter-on-quarter growth of 4.33% [3] Product Performance - The three core products (prebiotics, dietary fiber, and sugar-reducing sweeteners) generated revenue of 66,354.78 million yuan, a year-on-year increase of 32.15% [3] - Sugar-reducing sweeteners achieved revenue of 37,152.41 million yuan, growing by 61.22% [3] - Prebiotics generated revenue of 18,867.03 million yuan, with a year-on-year growth of 20.23% [3] - The revenue share of the three core products accounted for 47.42% of total revenue, an increase of 5.07% compared to the previous year [3] Cost Management - The overall gross margin for the first half of 2025 improved to 13.17%, up by 1.36% from the previous year [3] - The gross margin for the three core products was 17.94%, an increase of 1.93% year-on-year [3] - The company implemented cost control measures, including optimizing production processes and enhancing supply chain management to mitigate rising raw material costs [4] Business Development - In 2024, the company established projects for the annual production of 2,000 tons of DHA algae oil and 2,500 tons of HMOs (human milk oligosaccharides), which are expected to commence production in the second half of 2025 [5] - The company received approval for its HMO application as a new food nutrition fortifier in July 2025 [5] - The company is actively pursuing new product development in the field of synthetic biology, with several patents and trademarks registered in the first half of 2025 [6] Market Trends - The company noted that corn prices have been fluctuating, impacting production costs and gross margins [8] - The company’s products are primarily used in beverages, dairy products, functional foods, and health products, which typically do not exhibit significant seasonality [8] Strategic Initiatives - The establishment of a subsidiary in the United States is part of the company's strategy to enhance international business operations [9] - The company is focusing on expanding its market presence and product offerings in the field of synthetic biology and prebiotics [7]

Core Viewpoint - Tianjin Hesheng Biotechnology Co., Ltd. has completed a multi-million Pre-A round financing, which will accelerate its technological innovation in the synthetic biology field and lead new trends in health and nutrition solutions [1][2]. Group 1: Company Overview - Established in August 2023, Hesheng Biotechnology is a key technology transfer enterprise of Nankai University, gathering a leading research team in synthetic biology with nearly 30 years of experience [2]. - The company has developed a "DBTL" (Design-Build-Test-Learn) technical platform, utilizing proprietary gene element databases and self-developed AI algorithms to create high-productivity microbial strains [2]. - Hesheng Biotechnology has a comprehensive technical coverage from product research and development to downstream applications, focusing on probiotics, functional foods, and medical foods [2]. Group 2: Key Product Focus - Human Milk Oligosaccharides (HMOs) - The core technology for Hesheng Biotechnology's HMO products originates from the National Key Basic Research Program (973 Program), with the team first synthesizing HMOs in 2016 and obtaining invention patents for industrial strains [3]. - The company has developed several industrial strain construction technologies for HMOs, including 2'-FL, 3-FL, and others, with a product purity of 98.98%, significantly exceeding domestic and international quality standards [3][4]. Group 3: Research and Application - Hesheng Biotechnology is committed to independent innovation and has initiated research on the functional applications of HMOs, including their role in immune balance and disease intervention [4].